Ginkgo Biloba: study protocols
9 study groups say how much Ginkgo Biloba participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
1,725 products in our catalogue print how much Ginkgo Biloba a serving holds.
Most common: 100 mg to 250 mg, 33% of 1,725 products.
| Dose per serving | Products |
|---|---|
| 5 mg or less | 48 |
| 5 mg to 10 mg | 69 |
| 10 mg to 25 mg | 153 |
| 25 mg to 50 mg | 386 |
| 50 mg to 100 mg | 376 |
| 100 mg to 250 mg | 567 |
| 250 mg to 500 mg | 62 |
| over 500 mg | 64 |
Dose per serving from research
9 study groups in 9 studies say how much Ginkgo Biloba participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 100 mg to 250 mg, 78% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 7 |
| 250 mg to 500 mg | 2 |
Commonly used together
None of these 9 study groups took Ginkgo Biloba with anything else.
9 study groups
| Study | |||
|---|---|---|---|
| Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial 2011 · EGb 761 · Outpatients with mild to moderate Alzheimer’s disease, vascular dementia, or mixed dementia, with neuropsychiatric features; age and sex not reported | 240 mg | 24 weeks | 202 |
| Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg 2012 · EGb 761 group · Patients with mild to moderate dementia (Alzheimer's disease or vascular dementia) associated with neuropsychiatric symptoms | 240 mg | 24 weeks | 200 |
| EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure 1996 · EGb 761 group · Subjects taking part in a Himalayan expedition, with no stated age or sex; prevention of acute mountain sickness during gradual exposure to moderate altitude | 160 mg | — | 22 |
| Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial 2007 · EGb 761-treated patients · Patients with dementia and neuropsychiatric features, including probable or possible Alzheimer's disease or vascular dementia | 240 mg | 22 weeks | — |
| Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial 2009 · EGb 761 · Patients aged 50 years or above with dementia and neuropsychiatric features; subgroups had Alzheimer's disease or probable vascular dementia | 240 mg | 22 weeks | — |
| Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial 2012 · EGb 761® treatment · Outpatients aged 50 years or older with mild to moderate dementia, including Alzheimer's disease or vascular dementia, and neuropsychiatric features | 240 mg | 24 weeks | — |
| Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial 2017 · GBE group · Adults aged 18–80 with acute ischaemic stroke | 450 mg | 180 days | 179 |
| [Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia--a double blind study] 1997 · SXN group · People with chronic schizophrenia; age and sex not reported | 360 mg | 16 weeks | — |
| Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba 2005 · Ginkgo biloba supplementation · Healthy elderly adults, 67 ± 5.2 years; 6 men and 6 women | 240 mg | 4 weeks | 12 |